 |
Medscape Conference Coverage, based on selected sessions at the: 15th Conference on Retroviruses and Opportunistic Infections (CROI) February 3 - 6, 2008, Boston, Massachusetts This activity is not sanctioned by, nor a part of, the 15th Conference on Retroviruses and Opportunistic Infections.
Topic Overviews- CME Pathogenesis and Immune Response to HIV Infection
Physicians - maximum of 0.75 AMA PRA Category 1 credit(s)™ - HIV Immunopathogenesis and Correlates of Protection
Michael M. Lederman, MD - Virus and Host Factors in HIV Pathogenesis
Mario Stevenson, PhD
- CME Emerging Strategies in Antiretroviral Therapy: Clinical Trials in Naïve and Experienced Patients
Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™ - Clinical Trials: Advances in Antiretroviral Therapy for the Experienced Patient
Eric S. Daar, MD - Clinical Trials: Advances in Antiretroviral Therapy for the Naive Patient
Edwin DeJesus, MD
- CME Challenges in Antiretroviral Therapy: Complications, Pharmacology, and Resistance Issues
Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™ - Adverse Events and Complications of Antiretroviral Therapy
Ian M. Sanne, MD - Clinical Pharmacology of Antiretroviral Therapy
David M. Burger, PharmD, PhD - Antiretroviral Drug Resistance and Implications for Clinical Management of HIV Infection
William A. O'Brien, MD, MS
- CME Management of HIV Infection in Special Populations
Physicians - maximum of 0.75 AMA PRA Category 1 credit(s)™ - HIV/Hepatitis Virus Coinfections
Vincent V. Soriano, MD, PhD - Preventing Mother-to-Child Transmission and Pediatric HIV
Glenda E. Gray, MD, MBBCH, FCPaeds
- CME Prevention Strategies and Response to AIDS
Physicians - maximum of 1.0 AMA PRA Category 1 credit(s)™ - Emerging Strategies to Curb HIV Transmission
Susan Buchbinder, MD - Emerging HIV Vaccine Strategies
Susan Buchbinder, MD - Delivery of Care in Developing Countries
Guy de Bruyn, MBBCh, MPH
- CME Epidemiology and Management Strategies for HIV and Its Associated Infections
Physicians - maximum of 0.5 AMA PRA Category 1 credit(s)™ - Update on Epidemiologic Trends in HIV, Viral Hepatitis, and STDs
Michael L. Tapper, MD - Opportunistic Infections: Tuberculosis and HIV Coinfection
Gerald H. Friedland, MD
CME SpotlightExpert Interviews- Metabolic Comorbidities and Antiretroviral Therapy: An Expert Interview From CROI 2008 With Simon A. Mallal, MBBS, FRACP, FRCPADr. Simon A. Mallal discusses the latest data from CROI 2008 in regard to the metabolic comorbidities associated with HIV infection and antiretroviral therapy.
- Predicting Abacavir Hypersensitivity: An Expert Interview With Elizabeth J. Phillips, MD, FRCPC With VideoDr. Elizabeth Phillips discusses data that she and others presented at CROI '08 on abacavir hypersensitivity -- an important, and it seems now preventable, adverse event associated with this therapy.
- Highlights From the 15th Conference on Retroviruses and Opportunistic Infections: An Expert Interview With John G. Bartlett, MDRead Dr. Bartlett's impressions of the most significant research presented at CROI 2008, including data on metabolic complications, prevention strategies, OIs and coinfections, and the newest ART.
Conference News- "Prevention Cocktail" Needed to Reduce HIV Incidence Among MSMA combination of individual and community interventions may help decrease HIV incidence among men who have sex with men.
Medscape Medical News, February 8, 2008 - Gut Fibrosis Affects CD4+ Depletion and RepletionDepletion of CD4+ T cells during HIV infection, and their subsequent replacement after antiretroviral therapy, may be affected by fibrosis in the gut.
Medscape Medical News, February 7, 2008 - Scientific Obstacles to Effective HIV Vaccine Frustrate ResearchersTo overcome these obstacles, one expert recommends research focusing on broadly neutralizing antibodies and more aggressive pursuit of novel vaccine concepts, among other strategies.
Medscape Medical News, February 6, 2008 - Vaginal Lactobacillus Protects Against HIVLactobacillus, a key regulator of the vaginal ecosystem, also significantly reduces HIV-1 load in the vaginal tract, either directly or by suppression of pathogenic bacteria, investigators reported at the 15th Conference on Retroviruses and Opportunistic Infections here this week.
Reuters Health, February 6, 2008 - HIV Resistance Level Higher in Poor CountriesAlthough HIV-infected patients in resource-rich and resource-poor countries have comparable rates of compliance and response to first-line highly active antiretroviral therapy (HAART), there are disparities in the development of viral resistance to treatment.
Reuters Health, February 6, 2008 - Second Schering CCR5 Antagonist Shows Potency in Phase 1 TrialA phase 1 trial of SCH532702, a chemokine receptor 5 antagonist, demonstrated a profile of safety, pharmacokinetics, and viral suppression that justifies continued development.
Medscape Medical News, February 5, 2008 - Vicriviroc Data Lead to Phase 3 TrialData from the VICTOR E-1 study indicate that vicriviroc can act against HIV in treatment-experienced patients.
Medscape Medical News, February 5, 2008 - Some Adverse Effects of HIV Therapy Interruption PersistThe negative consequences of interrupting highly active antiretroviral therapy of HIV infection decrease after treatment resumes, but they do not return to pre-interruption levels, investigators reported here at the 15th Conference on Retroviruses and Opportunistic Infections.
Reuters Health, February 5, 2008 - Maternal HAART Reduces Breast Milk-Related HIV InfectionHIV transmission is significantly reduced in infants born to HIV-infected mothers who are on highly active antiretroviral therapy (HAART), when the infants are given a standard single-dose of nevirapine at birth, according to a 4-year study conducted in Kenya.
Reuters Health, February 5, 2008 - Extended Infant Prophylaxis Reduces HIV Transmission Via BreastfeedingUp to 50% of postnatal HIV infections from breastfeeding can be prevented by extending the standard nevirapine prophylaxis regimen, African and Indian investigators working in resource-poor settings reported Monday.
Reuters Health, February 5, 2008 - Circumcision Reduces Heterosexual Transmission of HSV-2 but Perhaps Not HIVIn a nested study, circumcision reduced the transmission of herpes simplex virus 2 but did not have an effect on the transmission of HIV.
Medscape Medical News, February 4, 2008
|
Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the 15th Conference on Retroviruses and Opportunistic Infections. These materials and the related activity are not sanctioned by the 15th Conference on Retroviruses and Opportunistic Infections or the commercial supporter of the conference and do not constitute an official part of that conference. Copyright © 2008 Medscape. |
|
|
